Norton Cancer Institute

Summary

Norton Cancer Institute is a medical facility located in Louisville, Kentucky. This center is recognized for care of Cancer, Lung Cancer, Pancreatic Cancer, Lymphoma, Breast Cancer and other specialties. Norton Cancer Institute is involved with conducting 220 clinical trials across 200 conditions. There are 13 research doctors associated with this hospital, such as John Hamm, MD, Don Stevens, MD, Jaspreet Grewal, MD, and Joseph Maly.

Top PIs

Clinical Trials running at Norton Cancer Institute

Non-Hodgkin's Lymphoma

Ovarian Cancer

Cancer

Multiple Myeloma

Breast Cancer

Lung Cancer

Pancreatic Cancer

Prostate Cancer

B-Cell Lymphoma

Colorectal Cancer

RNK05047

for Cancer

This trial tests RNK05047, a new drug, on patients with advanced solid tumors, including DLBCL. The drug is given regularly through an IV to find the safest and most effective dose.

Recruiting

1 award

Phase 1 & 2

REGN5837 + Odronextamab

for Aggressive B-Cell Lymphoma

The study is researching an experimental drug called REGN5837 in combination with another experimental drug, odronextamab (called "study drugs"). The aim of the study is to see how safe and tolerable the study drugs are, and to define the recommended dose for phase 2. The study is looking at several other research questions, including: * What side effects may happen from taking the study drugs * How much study drug is in the blood at different times * Whether the body makes antibodies against the study drugs (that could make the drugs less effective or could lead to side effects) * To find out how well the study drugs work against relapsed or refractory aggressive B-cell non-Hodgkin lymphomas (B-NHLs)

Recruiting

1 award

Phase 1

ACE1831 Cell Therapy

for B-Cell Lymphoma

This trial is testing ACE1831, a cell therapy made from healthy donors' immune cells, in patients with CD20-expressing Non-Hodgkin lymphoma. The therapy aims to use special immune cells to target and kill cancer cells with the CD20 marker. Rituximab, a monoclonal antibody targeting CD20, has been widely used in treating B-cell malignancies such as non-Hodgkin's lymphoma.

Recruiting

1 award

Phase 1